Together, this explains why DLBCL co-expressed with EBV and CD30 is characterized by enhanced NF-κB pathway activity, accelerated cell proliferation, and cell cycle progression. The gene discussed is TNFRSF8; the disease is diffuse large B-cell lymphoma.